Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

[1]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[2]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[3]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[4]  H. Shin,et al.  TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus , 2008, Rheumatology International.

[5]  David E. Misek,et al.  Integral Protein Microarrays for the Identification of Lung Cancer Antigens in Sera That Induce a Humoral Immune Response*S , 2008, Molecular & Cellular Proteomics.

[6]  R. Gomis,et al.  Cyclin-Dependent Kinase 4 Hyperactivity Promotes Autoreactivity in the Immune System but Protects Pancreatic β Cell Mass from Autoimmune Destruction in the Nonobese Diabetic Mouse Model1 , 2008, The Journal of Immunology.

[7]  D. Barnes,et al.  Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease , 2007, Cell.

[8]  Gil Mor,et al.  Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays , 2007, Proceedings of the National Academy of Sciences.

[9]  M. Alessio,et al.  Autoantibody signature in human ductal pancreatic adenocarcinoma. , 2007, Journal of proteome research.

[10]  M. Caron,et al.  Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery* , 2007, Molecular & Cellular Proteomics.

[11]  G. Rice,et al.  α2β1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis , 2007, Journal of Carcinogenesis.

[12]  M. Gore,et al.  Mucinous ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[13]  G. Moreno-Bueno,et al.  Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. , 2006, Human pathology.

[14]  Geoffrey J. McLachlan,et al.  A simple implementation of a normal mixture approach to differential gene expression in multiclass microarrays , 2006, Bioinform..

[15]  Weiliang Qiu,et al.  Development of a “reverse capture” autoantibody microarray for studies of antigen‐autoantibody profiling , 2006, Proteomics.

[16]  R. Priori,et al.  Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet's disease , 2006, Arthritis research & therapy.

[17]  R. Berkowitz,et al.  Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance , 2006, Clinical Cancer Research.

[18]  Gerard Tromp,et al.  Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. , 2006, Cancer research.

[19]  G. Rice,et al.  Role of Integrin Receptors for Fibronectin, Collagen and Laminin in the Regulation of Ovarian Carcinoma Functions in Response to a Matrix Microenvironment , 2005, Clinical & Experimental Metastasis.

[20]  J. Sudbø,et al.  beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. , 2005, European journal of cancer.

[21]  David E. Misek,et al.  An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer , 2004, Cancer Research.

[22]  M. Gore,et al.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Palmer,et al.  Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. , 2004, American journal of epidemiology.

[24]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[25]  J. Finke,et al.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. , 2003, Cancer research.

[26]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Ness,et al.  Cigarette Smoking and the Risk of Mucinous and Nonmucinous Epithelial Ovarian Cancer , 2002, Epidemiology.

[28]  Jianying Zhang,et al.  Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. , 2002, Autoimmunity reviews.

[29]  J. Collins,et al.  Autoantibody Responses to Carbohydrate Epitopes in Endometriosis , 2002, Annals of the New York Academy of Sciences.

[30]  G. A. Lang,et al.  Autoantibodies in endometriosis sera recognize a Thomsen-Friedenreich-like carbohydrate antigen. , 2001, Journal of autoimmunity.

[31]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[32]  T. Caputo,et al.  Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. , 2000, American journal of obstetrics and gynecology.

[33]  D. Cramer,et al.  Cigarette Smoking and Epithelial Ovarian Cancer by Histologic Type , 2000, Obstetrics and gynecology.

[34]  R. D'Agostino,et al.  Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2'-deoxyuridine (HMdU). , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  Robert E. Scully.  Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[36]  J. Shabanowitz,et al.  Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[38]  R. Berkowitz,et al.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.

[39]  R. Kryscio,et al.  Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. , 1992, Gynecologic oncology.

[40]  Joshua R. Ehrlich,et al.  The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens. , 2008, Methods in molecular biology.

[41]  Joshua R. Ehrlich,et al.  The 'reverse capture' autoantibody microarray:a native antigen-based platform for autoantibody profiling , 2006, Nature Protocols.

[42]  S. Dedhar,et al.  Signaling through beta-catenin and Lef/Tcf. , 1999, Cellular and molecular life sciences : CMLS.

[43]  N. Dubin,et al.  Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  S. Hirohashi,et al.  Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. , 1995, Invasion & metastasis.

[45]  M. Miwa,et al.  Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. , 1994, Cancer research.

[46]  R. Osborn.  Histological Typing of Ovarian Tumours. International Histology Classification of Tumours, S.F. Serov, R.E. Scully. World Health Organization, Geneva (1973), 56, Slides: £21.00, US$51.00, Book only: £6.65, US$16.50 , 1975 .

[47]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.